{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:06Z","timestamp":1740135126437,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006065","name":"Government of Western Australian, Department of Health","doi-asserted-by":"publisher","award":["Research Translation Project 2016 (Round 10)"],"award-info":[{"award-number":["Research Translation Project 2016 (Round 10)"]}],"id":[{"id":"10.13039\/501100006065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma. Australia is committed to eliminating hepatitis as a public health threat by 2030 set by the World Health Organization. However, since the introduction of funded DAA treatment, uptake has been suboptimal. Australia needs improved strategies for testing, treatment uptake and treatment completion to address the persisting hepatitis C public health problem. PLATINUM C is a HCV treatment registry and research platform for assessing the comparative effectiveness of alternative interventions for achieving virological cure.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PLATINUM C will prospectively enrol people with active HCV infection confirmed by recent detection of HCV ribonucleic acid (RNA) in blood. Those enrolled will agree to allow standardised collection of demographic, lifestyle, treatment, virological outcome and other relevant clinical data to better inform the future management of HCV infection. The primary outcome is virological cure evidenced by sustained virological response (SVR), which is defined as a negative HCV PCR result 6 to 18\u2009months after initial prescription of DAA therapy and no less than 12\u2009weeks after the completion of treatment. Study participants will be invited to opt-in to medication adherence monitoring and quality of life assessments using validated self-reported instruments (EQ-5D-5L).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>PLATINUM C is a treatment registry and platform for nesting pragmatic trials. Data collected will inform the design, development and implementation of pragmatic trials. The digital infrastructure, study procedures and governing systems established by the registry will allow PLATINUM C to support a wider research platform in the management of hepatitis C in primary care.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial is registered with the Australia and New Zealand Clinical Trials Register (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=376539\">ACTRN12619000023156<\/jats:ext-link>). Date of registration: 10\/01\/2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-05531-4","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T13:03:09Z","timestamp":1603976589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C"],"prefix":"10.1186","volume":"20","author":[{"given":"Jessica","family":"Ramsay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Pedrana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Andric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolajs","family":"Zeps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bellgard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-0638","authenticated-orcid":false,"given":"Tom","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"5531_CR1","unstructured":"Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"5531_CR2","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018","author":"The Kirby Institute","year":"2018","unstructured":"The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018."},{"key":"5531_CR3","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organisation","year":"2016","unstructured":"World Health Organisation. Global health sector strategy on viral hepatitis 2016\u20132021, 2016. Available from: \n                  http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/\n                  \n                ."},{"key":"5531_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.07.006","volume":"47","author":"N Scott","year":"2017","unstructured":"Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107\u201316.","journal-title":"Int J Drug Policy."},{"issue":"6","key":"5531_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/COH.0b013e32834bcb36","volume":"6","author":"J Grebely","year":"2011","unstructured":"Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS. 2011;6(6):501\u20137.","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl 2","key":"5531_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61\u201380.","journal-title":"Liver Int"},{"key":"5531_CR7","volume-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (august 2017)","author":"Hepatitis C Virus Infection Consensus Statement Working Group","year":"2017","unstructured":"Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (august 2017). Melbourne: Gastroenterological Society of Australia; 2017."},{"key":"5531_CR8","volume-title":"Viral Hepatitis Mapping Project: National Report 2018\u201319","author":"J MacLachlan","year":"2020","unstructured":"MacLachlan J, Smith C, Towell V, Cowie B. Viral Hepatitis Mapping Project: National Report 2018\u201319. Darlinghurst: Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM); 2020."},{"key":"5531_CR9","volume-title":"Gastroenterology and Liver Services, Remote Consultation Request for Initiation of Hepatitis C Treatment","author":"Gastroenterological Society of Australia","year":"2018","unstructured":"Gastroenterological Society of Australia. Gastroenterology and Liver Services, Remote Consultation Request for Initiation of Hepatitis C Treatment 2018. Available from: \n                  https:\/\/www.gesa.org.au\/public\/13\/files\/Hepatitis%20C\/Hep-C-remote-consultation-form-20191112.pdf\n                  \n                ."},{"issue":"10","key":"5531_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"5531_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","volume":"47","author":"P Read","year":"2017","unstructured":"Read P, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209\u201315.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"5531_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","volume":"3","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754\u201367.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5531_CR13","volume-title":"Monitoring hepatitis C treatment uptake in Australia (issue 10): the Kirby Institute, UNSW Sydney, Sydney NSW 2052","author":"Kirby Institute","year":"2019","unstructured":"Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (issue 10): the Kirby Institute, UNSW Sydney, Sydney NSW 2052; 2019; Available from: \n                  https:\/\/kirby.unsw.edu.au\/report\/monitoring-hepatitis-c-treatment-uptake-australia-issue-10-june-2019\n                  \n                ."},{"issue":"8","key":"5531_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jama.2015.7762","volume":"314","author":"DC Angus","year":"2015","unstructured":"Angus DC. Fusing randomized trials with big data: the key to self-learning health care systems? Jama. 2015;314(8):767\u20138.","journal-title":"Jama."},{"key":"5531_CR15","doi-asserted-by":"crossref","unstructured":"Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, et al. The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Ann Am Thorac Soc. 2020;6(6):501\u20137.","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"issue":"20","key":"5531_CR16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA."},{"key":"5531_CR17","volume-title":"Guidelines for Good Clinical Practice","author":"International Council for Harmonisation","year":"2016","unstructured":"International Council for Harmonisation. Guidelines for Good Clinical Practice 2016. Available from: \n                  http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4.pdf\n                  \n                ."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05531-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T05:13:02Z","timestamp":1604034782000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05531-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5531"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05531-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study investigators will ensure this trial is conducted in accordance with the principles of the Declaration of Helsinki [] and with the ICH Guidelines for Good Clinical Practice [].Ethics approval has been granted by Monash Health Human Research Ethics Committee (HREC\/45334\/MonH-2018-152902) and Western Australia Aboriginal Health Ethics Committee (868) Planned deviations from this protocol will not occur without approval from the relevant governing bodies. Informed consent will be documented in writing or electronically from all study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MH\u2019s institute receives funding from Gilead Sciences, Abbvie and BMS for investigator-initiated research. AP has received an honoraria from Gilead Sciences unrelated to this work. WC\u2019s institute has received funding from Merck & Co for investigator-initiated research. All other authors declare no financial or non-financial competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"802"}}